Dr. Dorothy Shaw MD
Dorothy Shaw, (MBChB, FRCSC, FRCOG, CEC, CCPE) is the Vice President, Medical Affairs for British Columbia's Women's Hospital & Health Centre, responsible for quality and safety in patient care using patient-centred, cost-effective approaches. She is a Clinical Professor in the Departments of Obstetrics and Gynaecology and Medical Genetics in the Faculty of Medicine at the University of British Columbia (UBC). Previous leadership roles at UBC include Associate Dean, Equity and Senior Associate Dean, Faculty Affairs in the Faculty of Medicine. Dr. Shaw is academically recognized through many peer reviewed papers and chapters, as well as the Executive Producer of an award winning film on insights into FGM, and is highly sought after as an invited speaker all over the globe. She is recognized for her contributions to the health and rights of women in Canada and globally and known for her collaborative approach in all aspects of her work to facilitate better outcomes, based on evidence. Dr. Shaw has received several highly prestigious awards in Canada and globally.
Dr. Shaw is Past President of the Society of Obstetricians and Gynaecologists of Canada (1991-1992) and was the first woman President of FIGO from 2006-2009. She was the inaugural chair of the FIGO Committee for Women's Sexual and Reproductive Rights from 2000-2003. Dr. Shaw piloted the formation of the Canadian Network for Maternal, Newborn and Child Health and in 2012 was the inaugural chair. Since 2014 she has continued to sit on the Network as a board member, and was appointed as Treasurer in 2017. She is a member of the WHO working group on MPDSR.
In July 2016, Dorothy was appointed as an Officer of the Order of Canada by Governor General David Johnson, for her work as an advocate for women’s health and reproductive rights.
Dorothy, with her husband Marc, is enjoying their first grandson and also loves to garden and walk in forests.
I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose.
I do not intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication).